New Pathway Identified: Splenic Tr1 Cells Drive Transplant Tolerance via Areg–EGFR Signaling
January 8, 2026
Brand Name :
N/A
Synonyms :
brilaroxazine
Class :
Atypical antipsychotic
Dosage Forms & Strengths
N/A
Brilaroxazine (FDA approval pending) is an investigational drug which is under development and is in phase III clinical trials
Not suggested
Refer to adult dosing
Actions and Spectrum
Brilaroxazine involves modulation of serotonin and dopamine receptors in the brain. It acts as a partial agonist at serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors.
Frequency not defined
None
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy consideration:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
Brilaroxazine is a serotonin-dopamine activity modulator. Its pharmacological effects involve interactions with serotonin and dopamine receptors in the brain.
Pharmacodynamics
Brilaroxazine acts as a partial agonist at dopamine D2 receptors. Modulation of D2 receptors is relevant to the treatment of schizophrenia, as dopamine dysregulation is implicated in these conditions.
Pharmacokinetics
Absorption
Brilaroxazine is administered orally and is absorbed into the bloodstream.
Distribution
Brilaroxazine is distributed throughout the body.
Metabolism
Brilaroxazine undergoes metabolism in the liver.
Excretion
Brilaroxazine is excreted through the feces.
Administration
Brilaroxazine is under investigation, and it is taken orally.
Patient information leaflet
Generic Name: brilaroxazine
Why do we use brilaroxazine?
Brilaroxazine (FDA approval pending) was being investigated for its potential as an antipsychotic in the treatment of schizophrenia and schizoaffective disorder.